Physician profile
Fabio Echavarria
NPI 1710984687
$4,582.08
in general payments reported to CMS, 2019-2025
30 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $831 · 2021: $684 · 2022: $250 · 2023: $625 · 2024: $873 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $817.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $782.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $594.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $497.31 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $338.06 | 2019-2025 | |
| Abbvie INC. | $183.69 | 2021-2024 | Qulipta |
| Abbott Laboratories | $140.42 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Exact Sciences Corporation | $132.72 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $115.95 | 2020-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $97.09 | 2021-2024 | |
| Esperion Therapeutics, INC. | $95.96 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.68 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $87.19 | 2019-2021 | |
| Eisai INC. | $69.96 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $61.55 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.49 | 2024-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $49.50 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $48.78 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $47.14 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $43.38 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.20 | 2019-2020 | |
| Inspire Medical Systems, INC. | $31.73 | 2024 | Inspire |
| Allergan, INC. | $25.86 | 2019-2020 | |
| Corcept Therapeutics | $24.37 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $24.11 | 2022 | |
| Gilead Sciences, INC. | $23.69 | 2020 | |
| Merck Sharp & Dohme LLC | $19.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.44 | 2023 | |
| Ibsa Pharma INC. | $12.94 | 2020 | |
| 3b Medical, INC. | $11.57 | 2023 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabio Echavarria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.